Biopharmaceutics In Early Drug Development - Overcoming Challenges For Small Molecules

Nominated candidates entering clinical development often have sub-optimal physicochemical, biopharmaceutic or DMPK properties for oral delivery. Development teams are challenged with how to understand the properties of new drug candidates, how to design the appropriate formulation strategy and how to move quickly and successfully into early phase clinical trials. Along the way, it is important to identify developability risks and take steps to mitigate these factors, balanced carefully against time and cost investments.

Join Chris Roe, Principal Research Fellow at Quotient Sciences, as he discusses effective strategies being used by biotech and pharmaceutical companies to overcome biopharmaceutic challenges for small molecules in today’s drug development pipeline; and explores alternative approaches for accelerating your early development plan. Chris will present case studies related to:

• Poorly soluble molecules
• Drugs with short half-lives
• Preclinical to clinical translation

Learn more about our services for Early Development here.